Keating Financial Advisory Services’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Keating Financial Advisory Services's REGN Position: Q2 2026 in Review
Keating Financial Advisory Services reduced its Regeneron Pharmaceuticals (REGN) stake by 9% in Q2 2026, selling an estimated $13.6K and leaving 203 shares worth $127K. The position accounts for 0.02% of the portfolio, ranked #441.
Keating Financial Advisory Services first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $172K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Keating Financial Advisory Services held 203 shares of Regeneron Pharmaceuticals worth $127K as of Q2 2026.
- Keating Financial Advisory Services sold 20 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $13.6K.
- Regeneron Pharmaceuticals made up 0.02% of Keating Financial Advisory Services's portfolio in Q2 2026, its #441 holding.
- Keating Financial Advisory Services first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
- Keating Financial Advisory Services's Regeneron Pharmaceuticals position peaked at $172K in Q1 2026.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.